- References (2)
- Inventor Info
|Applications||ELISA IHC IP WB|
|Antigen/Gene or Protein Targets||ASAP1|
|Reactivity||Human and Rat|
|Relevance||ASAP1 possesses phosphatidylinositol 4,5-biphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. It may coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. It potentially has involvement in tumour progression, having been shown to promote metastasis formation in vivo and stimulate tumor cell motility, invasiveness, and adhesiveness in vitro. ASAP1 represents a potential target for cancer therapy.|
|Immunogen||Recombinant Protein (fragment of human ASAP1 (corresponding nucleotides 977-1532 of KIAA1249) with N-terminal GST tag produced in E.coli strain BL-21)|
|Positive Control||Human: HT29 and MDA-MB-231 Rat: ASAP1 is strongly expressed in ASML and weakly expressed in 1AS pancreatic carcinoma cells.|
|Recommended Growing Conditions||10% FCS + RPMI + Pen/Strep|
Other research areas applicable: Metastasis, cytoskeleton, vesicle trafficking.
WB WB: Use a concentration of 1 µg/ml. Predicted molecular weight: 125 kDa.
IHC-P IHC-P: Use a concentration of 5 µg/ml.
IHC-Fr IHC-Fr: Use a concentration of 5 µg/ml.
IP IP: Use a concentration of 10 µg/ml.
ELISA ELISA: Use at an assay dependent concentration.
|Research Area||Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction|
There are 2 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor